Population pharmacokinetic‐pharmacodynamic modelling of platelet time‐courses following administration of abrocitinib

AIMS: Abrocitinib is a selective Janus kinase 1 inhibitor for the treatment of moderate‐to‐severe atopic dermatitis. Herein we describe the time‐course of drug‐induced platelet reduction following abrocitinib administration, identify covariates affecting platelet counts, and determine the probabilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wojciechowski, Jessica, Malhotra, Bimal K., Wang, Xiaoxing, Fostvedt, Luke, Valdez, Hernan, Nicholas, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544602/
https://www.ncbi.nlm.nih.gov/pubmed/35342978
http://dx.doi.org/10.1111/bcp.15334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544602/
https://www.ncbi.nlm.nih.gov/pubmed/35342978
http://dx.doi.org/10.1111/bcp.15334

Ejemplares similares